



**SAR HEALTHLINE (P) LTD**

## **Hyaluronidase 80U/mL in HEPES-HTF with 5mg/mL HAS**

**For laboratory procedures only; other uses must be qualified by the end user.**

### **Product Description**

Hyaluronidase 80U/mL in HEPES-HTF

### **Catalogue Code**

ART-4007-A

### **Unit Size**

6 x 1.0mL

### **INTENDED USE**

Hyaluronidase is an enzyme found in high concentration in the acrosome of most mammalian spermatozoa. It randomly attacks the hexosaminidic linkage of hyaluronic acid, the glycosaminoglycan that makes up the extracellular matrix holding cumulus cells together. Prior to intra-cytoplasmic sperm injection (ICSI), the cumulus cells have to be removed from the oocyte so that there is a clean surface on the zona pellucida to permit the easy handling of the oocyte with microtools for holding and injection. Brief exposure of the oocyte-cumulus masses to hyaluronidase solution digests the hyaluronic acid holding the cumulus cells together. The cumulus cells can then be more easily removed mechanically by pipetting the oocyte-cumulus mass through fine bore pipettes slightly larger than the diameter of the oocyte.

### **COMPONENTS**

Bovine hyaluronidase at 80U/mL in HEPES-HTF with 5mg/mL Human Serum Albumin (HSA).

### **STORAGE INSTRUCTIONS AND STABILITY**

Store unopened containers at or below -20°C upon receipt. Warm to incubator (37°C) temperature prior to use. Exposure of the medium to CO<sub>2</sub> should be minimized to avoid pH levels of 7.0 or less. Do not refreeze or expose to temperatures of greater than 39°C. After thawing, unused product can be kept refrigerated at 2-8°C for 3 weeks before discarding. The product is stable until the expiration date shown on the label or within 30 days of the Date of First Use provided that proper aseptic procedures have been observed by the user:

- A. Remove desired volume of product using aseptic procedures.
- B. Once product has been removed from the original container, reseal the container to ensure a tight seal. Write the date the product was first opened on the product label. Do not use product longer than 30 days after opening the container.
- C. Once removed, do not return any volume of product to the original container.
- D. Once the product has been opened, store the sealed container at 2-8°C.
- E. Do not use if the product becomes discoloured, cloudy, turbid, or shows any evidence of microbial contamination.

One-cell MEA tested and passed with 80% or greater blastocyst. USP Endotoxin gel clot tested and passed with <1 EU/ml. A Certificate of Analysis is available for this product.

### **DIRECTIONS FOR USE**

Oocyte-cumulus complexes (OCC) can be placed in a drop of hyaluronidase medium (100microL) under oil. After 30 to 45 seconds, the OCCs are pipetted in and out of a fine-bore glass pipette to loosen the weakened cumulus mass and release the oocyte with attached corona radiata cells. The oocyte is then transferred to a 100microL drop of Quinn's Advantage™ Medium with HEPES containing 5mg/mL

HSA and the corona radiata cells removed by gentle pipetting using a narrow-bore glass pipette. The first pipette used to remove the oocyte with adhering corona radiata cells from the cumulus mass should have an inside diameter 250 to 300  $\mu$ m. The second pipette for the removal of the corona radiata cells should have a diameter of about 135  $\mu$ m. The cumulus-free oocytes are further washed through a series (4-5) of 100-  $\mu$ L drops of Quinn's Advantage™ Medium with HEPES containing 5mg/mL HSA to remove excess hyaluronidase and detached cumulus cells. The oocytes are now ready for the ICSI procedure.

**Each laboratory should make its own determination of which medium to use for each particular procedure.**

Information on specific aspects of IVF and embryo culture is available in our publication "IVF Laboratory Policy and Procedure Manual".

**PRECAUTIONS AND WARNINGS**

Do not use medium that shows evidence of particulate matter, cloudiness or is not rose colored. To avoid problems with contamination, practice aseptic technique and discard minimal amounts of excess medium remaining in the bottle. This product contains albumin, a derivative of human blood. All donors used in its manufacture were individually tested and found to be nonreactive for hepatitis B surface antigen (HBsAG) and antibodies to hepatitis C virus (HCV) and human immunodeficiency virus (HIV) by approved testing methods. Donors of the source material have been screened for Creutzfeldt Jakob disease (CJD). Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases. A theoretical risk for transmission of CJD is also considered extremely remote. No cases of transmission of viral diseases or CJD have ever been identified for albumin.